Clinical Trial Update: Thymosin Alpha-1 for irAE Secondary to ICIs [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update for Thymosin Alpha-1 addressing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-related Adverse Events
• Iraes

Drugs mentioned

• Thymosin alpha-1 (thymosin alpha-1)

Snippet

Sponsor: Jun Wang | Conditions: IrAE | Phase 4 | Status: UNKNOWN